Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Sosei Group Corporation
Sosei Group Corporation
Activities:
Ingredients
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Metrion and Sosei Heptares to explore structure-based drug design
Sosei Heptares will have exclusive global rights to all molecules identified
Research & Development
Sosei Heptares and PharmEnable enter drug discovery collaboration
The companies will jointly conduct and share the costs of the discovery and development program and will co-own any resulting products
Research & Development
Sosei Heptares announces €40 million Medicxi investment
Two asset-centric companies have been formed to develop Sosei’s novel therapies for neurological diseases funded by Medicxi
Recruitment
Sosei appoints Interim CFO
Media
Changes in executive management at Sosei
Manufacturing
Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017
Finance
Heptares Therapeutics enters agreement with Daichi Sankyo
The collaboration aims to discover and develop novel, small-molecules for the treatment of pain
Subscribe now